In 2025, BioMark Diagnostics secured ISO 15189 certification documents in December, setting the stage for CLIA and CAP accreditation and enabling U.S. market entry. The company doubled laboratory throughput capacity and completed a 7,000-patient lung cancer diagnostic study—the largest in Canada—providing robust real-world evidence for its liquid biopsy platform. BioMark was selected as the exclusive partner for the 10,000-patient HANSE trial, the biggest prospective lung cancer study since 2013, and published six peer-reviewed articles in high-impact journals. The firm also raised $4.5 million in equity financing, secured NRC Horizon Europe support for its European expansion, and received grants from the Manitoba Lung Association and the City of Quebec to pilot a First Nations lung cancer detection program.

On December 30, 2025, BioMark appointed Mr. James Lavender—an experienced technology investor and AI growth strategist—to its Board of Directors following shareholder approval at the December 22 AGM. Lavender led a major financing round in March 2025 and has forged relationships with state-level U.S. organizations and strategic investment groups. His software development and enterprise sales expertise will guide BioMark’s commercialization efforts, certification finalization, and lab services rollout, reinforcing the company’s strategy to scale AI-driven metabolomics diagnostics.

Throughout 2026, BioMark aims to secure ISO 15189 accreditation and submit CLIA/CAP applications, unlocking access to more than 16 million at-risk U.S. individuals requiring annual lung cancer screening. The company plans to publish HANSE trial data and the 7,000-patient study in high-impact journals to fuel pharma and laboratory licensing negotiations. Commercial milestones include launching ISO-certified diagnostic services, expanding distribution through medical and clinic chains, and developing a U.S. reimbursement strategy with payors. Follow-on funding is targeted to build on clinical validation and revenue traction, while new leadership hires in patient engagement, revenue generation, and clinical operations will support scalable growth.